MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy 2. Juni 2012 Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012. J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4 (0327), 141–142. Abstract MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy. Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012. Weiterlesen Quality of life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine – second interim analysis of the German non-interventional study (NIS). Steffens, C., Zaiss, Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Marschner, N., Hurst, U., Mueller, V., 2012. J Cancer Res Clin Oncol 138(Suppl.1)(0085), 67. doi:10.1007/s00432-011-1144-4… Weiterlesen